Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02267317 · ClinicalTrials.gov registry record · Phase 2
The Effect of TLR4 Inhibition in Obese and Type 2 Diabetic Subjects
A Phase 2 study, sponsored by The University of Texas Health Science Center at San Antonio.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT02267317 is a Phase 2 study that was terminated before completion, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 15 participants.
The verdict
NCT02267317, a Phase 2 study, was terminated before completion, sponsored by The University of Texas Health Science Center at San Antonio.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
To determine whether pharmacologic inhibition of Toll-like receptor 4 (TLR4) with eritoran for injection (E5564) will reduce inflammation and improve glucose metabolism in insulin resistant (obese and T2DM) subjects.
Interventions
- DRUG D5W
- DRUG Eritoran
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2015-01 |
| Est. Completion | 2018-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02267317
The ClinicalTrials.gov registry entry for NCT02267317 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which D5W is the first listed.
NCT02267317 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02267317 about?
NCT02267317 is a clinical study titled "The Effect of TLR4 Inhibition in Obese and Type 2 Diabetic Subjects". To determine whether pharmacologic inhibition of Toll-like receptor 4 (TLR4) with eritoran for injection (E5564) will reduce inflammation and improve glucose metabolism in insulin resistant (obese and T2DM) subjects.
What is the current status of trial NCT02267317?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2015-01. Estimated completion is 2018-09.
What interventions are being tested in trial NCT02267317?
The interventions under investigation include: D5W (DRUG), Eritoran (DRUG).
Who is sponsoring clinical trial NCT02267317?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.